The RAS/RAF/MEK/ERK signaling pathway has been largely unexplored as a potential had minimal effect on AZD6244-induced cell death. Altogether, these findings show that the novel anti-MEK agent, AZD6244, induced apoptosis in DLBCL and that cell death was BIM-dependent.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults accounting for nearly 35% of all non-Hodgkin's lymphomas (NHL). Significant advances have been in the treatment of DLBCL, particularly with immunochemotherapy, however approximately 30-40% of patients still die from this malignancy. Additionally, short-and long-term toxicities of chemotherapy, including secondary malignancies and leukemias, continue to adversely impact the long-term prognosis of patients. Continued investigations of novel targeted therapeutic agents in DLBCL are warranted.
The RAS/RAF/mitogen-activated protein kinase 1/2 (MEK1/2)/extracellular signal-regulated kinase 1/2 (ERK1/2) plays a prominent role in cancer biology, including hematologic malignancies, in part through the regulation of cell growth and proliferation. [1] [2] [3] [4] [5] Activating mutations in RAS and RAF lead to aberrant activation of their downstream target, MEK1/2. Directly downstream of MEK1/2, ERK1 and ERK2 are intimately involved in transducing signals from growth factor receptors and cytokine receptors following ligand binding. 2 Further, ERK is the only known catalytic substrate of MEK. 6 We and others have shown that the MEK/ERK signaling pathway is constitutively active in a large number of cancers, including hematologic malignancies. 3, 4, [7] [8] [9] Moreover, the MEK/ERK signal transduction cascade has been shown to be susceptible to pharmacologic intervention. Thus, MEK has emerged as an attractive therapeutic target in cancer.
The majority of pre-clinical, and especially clinical trial data studying MEK inhibitors to date have emerged largely from solid tumor studies. [10] [11] [12] [13] [14] We recently showed in pre-clinical studies that inhibition of ERK1/2 phosphorylation by 1st generation MEK and ERK inhibitors correlated with significant cell death in a lymphoma tumor model, 15 while others showed that sub-lethal concentrations of a 1 st generation MEK antagonist, sorafenib, was effective in lymphoma cells. 16 Furthermore, we recently
For personal use only. on July 16, 2017 . by guest www.bloodjournal.org From demonstrated that MCT-1, an oncogene directly downstream of MEK/ERK, is overexpressed in the vast majority of primary DLBCLs . 15 MCT-1 is known to co-localize with ERK1/2, while phosphorylation of MCT-1 protein by ERK is critical for stabilization of MCT-1 protein and for its functional ability to promote cell proliferation. 15, 17 ARRY-142886 (AZD6244, selumetinib; Astra Zeneca) is a selective non-ATPcompetitive 2 nd generation oral MEK inhibitor studied primarily in solid tumor studies with reported nanomolar activity against purified MEK1 enzyme. [18] [19] [20] [21] [22] [23] Furthermore, phase I and phase II solid tumor clinical trials have shown this agent to be well-tolerated and have encouraging clinical efficacy. [24] [25] [26] [27] To our knowledge, minimal data are available on MEK inhibitors in lymphoma and moreover, this newer anti-MEK agent has never been examined in lymphoma. We sought to examine the mechanisms of action and cytotoxic effect of the novel 2 nd generation MEK small molecule antagonist, AZD6244, in lymphoma cell lines, primary cells, and an in vivo human DLBCL xenograft model.
Materials and Methods
Cell culture and treatment DLBCL germinal center cell lines (SUDHL4, SUDHL6, SUDHL10, and OCI-LY19) and the non-germinal center cell line, OCI-LY3, were grown in RPMI 1640 (Invitrogen) containing 10% fetal bovine serum. The 2 nd generation MEK inhibitor AZD6244 was supplied from Astra Zeneca.
MTT proliferation analysis
In 
Apoptosis assays
DLBCL cell lines were seeded at equal density and then treated with AZD6244 in complete RPMI 1640 medium. Forty-eight hours after treatment, cells were harvested and apoptosis was analyzed by flow cytometry using the Annexin V/PI staining kit (BD Biosciences). The significance of differences between experimental conditions was determined using the Student's t test.
Soft agar colony-forming assay
SUDHL4 and OCILY3 cells were incubated with nanomolar concentrations of AZD6244 in the soft agar to form colonies as previously described. 15 The number of colonies in each well was counted. Colony formation (>50 cells) was examined under phasecontrast microscopy. Images were taken at room temperature using a Nikon Eclipse TE-2000S microscope. Each experiment was conducted several times and the significance of differences between experimental conditions was determined using the Student's t test.
Primary DLBCL cells
Following approval by the Northwestern University Institutional Review Board (IRB) and written informed consent in accordance with the Declaration of Helsinki, peripheral blood was drawn from three patients with leukemic phase of DLBCL. Each of these three patients had relapsed disease following prior rituximab/cytotoxic chemotherapy. Two of the three patients had a CD10+ germinal center phenotype, while the third appeared to have a non-germinal center DLBCL subtype (i.e., CD10-negative and Bcl-6-negative). All peripheral blood was diluted 1:1 with PBS (Ca 2+ and Mg 2+ free) and was layered on top
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In vivo human lymphoma xenograft model
Female severe combined immunodeficient mice (SCID) beige mice were housed in a pathogen-free environment under controlled conditions of light and humidity and received food and water ad libitum. SUDHL6 cells (2 x 10 6 ) were re-suspended in 100µL
PBS and then mixed with an equal volume of Matrigel. The mixture was injected subcutaneously into the left and right dorsal flanks of 5-to 7-week-old female SCID mice.
When the tumor reached the size of 60 to 160mm 3 , the drug (AZD6244) was administered by intraperitoneal injection every other day at a dose of 10 mg per kilogram of body weight for a total of 3 weeks. Injection of the vehicle alone (5% DMSO in 0.05mol/L PBS) was used as a control. The significance of differences between treatment arms was determined using the Student's t test.
Cell cycle analysis
Distinct phases of the cell cycle were distinguished by DNA staining with the fluorescent dye propidium iodide and measured by flow cytometry. Cells were washed in ice cold PBS, fixed in 70% ethanol, and stained for 30 minutes at 37°C with propidium iodide (50μg/ml propidium iodide in hypotonic sodium citrate solution containing 50μg/ml RNase)
followed by flow cytometric analysis. The percentages of cells in G1, S, and G2/M phases were determined using the cell cycle analysis program Modfit LT (Verity Software House, Topsham, ME).
Western blot analysis
Cells were centrifuged, washed with cold PBS, and lysed on ice for 30 minutes in lysis buffer containing protease and phosphatase inhibitors. Protein concentrations were 
Plasmids and transfections
ERK1, ERK2, and BIM were knocked down using GIPZ lentiviral shRNA from Open 
Results

AZD6244 inhibits ERK phosphorylation levels in DLBCL cells
Since ERK is the only known direct substrate for MEK, we examined whether inhibition of MEK with AZD6244 affected ERK phosphorylation. Figure 1D ). Furthermore, we corroborated our small inhibitory molecule inhibition using a genetic approach. ERK2 was knocked down in OCI-LY3 cells using lentivirus-based ERK2 shRNA; ERK2 knockdown was confirmed by western blotting ( Figure 1E ). OCI-LY3 cells were treated with 200nM or 300nM of AZD6244 for 48 hours following transduction of ERK2 shRNA. AZD6244-induced apoptosis was increased in the presence of ERK2 shRNA at both concentrations compared with control, however this difference was not significant (p>0.05) ( Figure 1F ). We further investigated cell death following knock down of both ERK1 and ERK2 concurrently in OCI-LY3 and OCI-LY19 cell lines. Knock down with ERK1 and ERK2 together appeared to cause slightly increased apoptosis in these cells compared to either construct alone (OCI-LY3 more so than OCI-LY19), however these results were not significant (Supplementary Figure 1) . We next examined induction of apoptosis in DLBCL cell lines following AZD6244. Figure 2C shows >70% apoptosis in SUDHL4 and >40% apoptosis in SUDHL6 with 200nM, while OCI-LY19 and OCI-LY3 show approximately 60% apoptosis with 300nM AZD6244. DLBCL patient peripheral blood monocytes were also exposed to increasing concentrations of AZD6244 (i.e., 25nM to 400nM) for 24 and 72 hours ( Figure 2D ).
Disruption of cell cycle progression, growth inhibition, reduction in clonogenic capacity, and induction of apoptosis
AZD6244 induced apoptosis in primary cells at concentrations as low as 100nM.
Altogether, the half maximal inhibitory concentration (IC 50 ) for in vitro and primary cells was 100nM-300nM. Notably, there were no differences in apoptosis noted based on germinal center vs non-germinal center DLBCL subtype (data not shown).
Antitumor efficacy of AZD6244 in a DLBCL SCID xenograft model
We examined whether AZD6244 inhibits lymphoma growth in a SCID xenograft DLBCL mouse model. As shown in Figure 2E , 10mg/kg of AZD6244 effectively inhibited tumor growth in a SUDHL6 xenograft. At this drug dose, no lethal toxicity or significant weight loss were observed among treated animals compared with control mice (data not shown). From 28 weeks on, mice treated with AZD6244 had significantly decreased average tumor volume compared with control (p<0.05).
Drug inhibition and genetic manipulation of MEK
We also tested level of cell death following dominant negative MEK1 as well as with use of the MEK 1/2 inhibitor, PD09895, alone or in the presence of constitutively active MEK1. We assessed pERK levels following OCI-LY3 cells transfected with constitutively active MEK1 subsequently treated with PD098059 or AZD6244. Unlike AZD6244-treated cells, appreciable pERK levels were detectable with PD98059 exposure in the presence of constitutively active MEK1 in OCI-LY3 cells, albeit less than untreated cells ( Figure 3A) . Furthermore, constitutively active MEK1 transfection resulted in partial inhibition of AZD6244-induced apoptosis. Interestingly, PD98059 had minimal apoptotic effect in Raji or OCI-LY3 cells ( Figure 3B ) as well as other cell lines (data not shown).
We also transfected OCI-LY19 and OCI-LY3 cells with dominant negative MEK1. Dominant negative MEK1 resulted in increased levels of apoptosis compared with vector control ( Figure 3C ).
Caspase-dependent cell death
To assess the role of caspase activation in AZD6244-induced apoptosis, caspases and PARP were measured. As shown in Figure 3A Figure 4D ), apoptosis was blocked most prominently with the pan-caspase inhibitor Z-VAD. Collectively, these data suggest that AZD6244-induced apoptosis is predominantly regulated by extrinsic pathways.
AZD6244 modulates the expression of cell cycle and apoptosis regulating proteins
We next analyzed the effect of AZD6244 on the expression of key regulators of cell cycle progression and apoptosis by immunoblot analysis. Figure 5A shows a significant decrease in c-MYC, BCL2 and MCL-1 following AZD6244 treatment in all DLBCL cell Figure 6B ). An increase in PUMA and BIM expression was also observed in primary DLBCL cells following AZD6244 exposure ( Figure 6C ).
Furthermore, to confirm the role of BIM in AZD6244-induced apoptosis, we knocked down BIM in SUDHL4 and OCI-LY3 cells using BIM siRNA. As shown in Figure   6D (OCI-LY3) and Figure 6E (SUDHL4), BIM knock down diminished the apoptotic effect Figure 7C ). In addition, we further confirmed AKT-mediated resistance by transfecting OCI-LY3 cells with constitutively active AKT construct followed by incubation with AZD6244. Cells transfected with constitutively active AKT showed a slight reduction in AZD6244-induced apoptosis ( Figure 7D ). These findings showed that AKT activation has minimal effect on anti-MEK AZD6244-induced apoptosis.
Discussion
Altogether, these data show that the 2 nd generation MEK small molecule inhibitor, and phase II trials of advanced, refractory colorectal, melanoma, and lung cancer. [25] [26] [27] AZD6244 has been examined in leukemia and myeloma models, [42] [43] [44] however to our knowledge, has never been tested in lymphoma.
In a spectrum of DLBCL cell lines (i.e., germinal center and non-germinal center), At the cellular and molecular level, the BCL-2 family represents a critical checkpoint for the hierarchical regulation of apoptosis. [45] [46] [47] Others have shown that cell death of acute myelogenous leukemia cells with the 1 st generation MEK inhibitor PD184352 (CI-1040) in combination with other agents (e.g., perifosine 48 ) was dependent in part on the BCL-2 family. Meng et al showed that BIM in particular was key to AZD6244-induced apoptosis in a lung cancer model. 48 We found here that AZD6244 shRNA knock out decreased apoptosis, while Bcl-2 over expression did not.
An exciting finding in this study was that forced AKT activation through a constitutively active construct or inhibition of AKT (through genetic silencing or chemical inhibition) had no significant effect on AZD6244-induced apoptosis. However, other pathways we found to be affected by AZD6244 included FOXO3a, p27 KIP1 , and c-MYC.
Continued examination of these and other signaling pathways will be important in further delineating the cell death mechanisms for this and other novel anti-MEK small molecule agents. In addition, clinical study of AZD6244 in DLBCL is warranted, while the overall role of the MEK/ERK signaling cascade in lymphomagenesis should continue to be investigated.
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